LGND News and Press, Ligand Pharmaceuticals Incorporated From 09/22/23

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been granted marketing authorization by the European Commission (EC) for Enrylaze ® (JZP458; a recombinant Erwinia asparaginase or crisantas...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) (“Travere”) today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI ® ...

2023-09-18 18:46:31 ET More on Ligand Pharmaceuticals Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earnings data for Ligand Pharmaceuticals Financial information for Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out ...

Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biology Ligand contributes $15 million in exchange for economic interest in select Primrose programs Ligand improves cash expens...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on September 1, 2023, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 50,000 shares of its common sto...

2023-09-01 11:37:32 ET Summary Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodextrin used in drug development. Captisol has been a major source of revenue for Ligand, particularly t...

2023-08-10 08:06:33 ET More on Johnson & Johnson Future Prospects For Johnson & Johnson Following Strong Q2 Performance Johnson & Johnson: Resilient, But Clarification On Liability Issue Is Needed Johnson & Johnson ( JNJ ) Q2 2023 Earnings Call ...

2023-08-08 22:52:07 ET Ligand Pharmaceuticals Incorporated (LGND) Q2 2023 Earnings Conference Call August 8, 2023 16:30 ET Company Participants Simon Latimer - Head, Investor Relations Todd Davis - Chief Executive Officer Tavo Espinoza - Chief Financial Officer ...

2023-08-08 17:42:33 ET Ligand Pharmaceuticals press release ( NASDAQ: LGND ): Q2 Non-GAAP EPS of $1.42 beats by $0.76 . Revenue of $26.4M (-47.3% Y/Y) beats by $0.67M . For further details see: Ligand Pharmaceuticals Non-GAAP EPS of $1.42 beats by $0.76, ...

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a confere...